Related Experiment Video
Updated: May 10, 2025
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
PCSK-9 Inhibitors Can Significantly Improve the Coronary Slow Flow Caused by Elevated Lipoprotein (a) in ST-Elevation
Hao Xu1, Ziqing Wang1, Dan Chen1
1Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao Municipal Key Laboratory of Hypertension (Key Laboratory of Cardiovascular Medicine), Qingdao, Shandong Province, China.
Insights
Elevated lipoprotein (a) [Lp(a)] is a key risk factor for coronary slow flow after percutaneous coronary intervention in patients with chronic kidney disease (CKD). Proprotein convertase subtilisin/kexin Type 9 (PCSK-9) inhibitors improve outcomes in these high-risk individuals.
Area of Science:
- Cardiology
- Nephrology
- Biochemistry
Background:
- Coronary slow flow and no-reflow phenomena are linked to poor prognosis in acute myocardial infarction (AMI), particularly in patients with chronic kidney disease (CKD).
- Identifying contributing factors is crucial for mitigating ischemic events and improving patient outcomes.
Purpose of the Study:
- To investigate the association between elevated lipoprotein (a) [Lp(a)] levels and proprotein convertase subtilisin/kexin Type 9 (PCSK-9) inhibitor therapy.
- To determine the impact on coronary slow flow or no-reflow after percutaneous coronary intervention (PCI) in AMI patients with CKD.
Main Methods:
- A cohort of 323 ST-elevation myocardial infarction (STEMI) patients undergoing PCI was analyzed.
- Patients were stratified by CKD status and Lp(a) levels; logistic regression identified risk factors, and PCSK-9 inhibitor impact was assessed.
Main Results:
- STEMI patients with CKD exhibited significantly higher Lp(a) levels.
- Elevated Lp(a) was an independent risk factor for coronary slow flow/no-reflow post-PCI in CKD patients.
- PCSK-9 inhibitors improved coronary blood flow and reduced cardiovascular events in CKD patients with elevated Lp(a).
Conclusions:
- Elevated Lp(a) is a significant independent risk factor for coronary slow flow/no-reflow after PCI in STEMI patients with CKD.
- PCSK-9 inhibitor therapy demonstrates efficacy in improving coronary flow and reducing cardiovascular events in this patient population.
Background:
Coronary slow flow and no reflow significantly predict poor prognosis in acute myocardial infarction (AMI) patients, especially those with chronic kidney disease (CKD). Early identification of factors contributing to these conditions can mitigate ischemic events and improve outcomes.
Aims:
This study aimed to investigate the association between elevated lipoprotein (a) [Lp(a)] levels and proprotein convertase subtilisin/kexin Type 9 (PCSK-9) inhibitor therapy with coronary slow flow or no reflow after percutaneous coronary intervention (PCI) in AMI patients with CKD.
Methods:
A total of 323 ST-elevation myocardial infarction (STEMI) patients who underwent PCI between October 2017 and June 2023 were included. Patients were divided into CKD (n = 132) and non-CKD (n = 191) groups. Lp(a) levels and the prevalence of coronary slow flow or no reflow after PCI were evaluated. STEMI patients with CKD were further categorized into elevated Lp(a) (n = 81) and normal Lp(a) (n = 51) subgroups. Logistic analysis identified risk factors for coronary slow flow/no reflow after PCI. The impact of PCSK-9 inhibitors on outcomes was also assessed in the elevated Lp(a) subgroup.
Results:
STEMI patients with CKD had significantly higher Lp(a) levels compared to those without CKD (median 36.75 vs. 15.90 mg/dL, p = 0.0001). CKD patients with elevated Lp(a) had a higher prevalence of coronary slow flow/no reflow after PCI than those with normal Lp(a) (38.3% vs. 13.7%, p = 0.002). Logistic regression analysis identified elevated Lp(a) as an independent risk factor for slow flow/no reflow after PCI in STEMI patients with CKD (OR = 2.985, p = 0.027). In CKD patients with elevated Lp(a), PCSK-9 inhibitors significantly improved post-PCI coronary flow and reduced composite cardiovascular events during 1-year follow-up (22.2% vs. 51.1%, p = 0.008).
Conclusions:
Elevated Lp(a) is an independent risk factor for coronary slow flow or no reflow after PCI in STEMI patients with CKD. PCSK-9 inhibitors improve coronary blood flow and reduce cardiovascular events in these patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:31Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...